Head to Head Contrast: Nuvo Pharmaceuticals (OTCMKTS:MRVFF) versus Biofrontera (NASDAQ:BFRI)

Nuvo Pharmaceuticals (OTCMKTS:MRVFF) and Biofrontera (NASDAQ:BFRI) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings and analyst recommendations.

Risk and Volatility

Nuvo Pharmaceuticals has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500. Comparatively, Biofrontera has a beta of 0.78, meaning that its stock price is 22% less volatile than the S&P 500.

Earnings and Valuation

This table compares Nuvo Pharmaceuticals and Biofrontera”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvo Pharmaceuticals	$54.98 million	0.20	-$25.70 million	($0.12)	-8.16
Biofrontera	$41.71 million	0.54	-$10.54 million	($0.45)	-3.38

Biofrontera has lower revenue, but higher earnings than Nuvo Pharmaceuticals. Nuvo Pharmaceuticals is trading at a lower price-to-earnings ratio than Biofrontera, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Nuvo Pharmaceuticals and Biofrontera’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nuvo Pharmaceuticals	20.88%	-1,996.22%	14.25%
Biofrontera	-13.78%	-145.81%	-31.30%

Insider and Institutional Ownership

10.1% of Biofrontera shares are owned by institutional investors. 7.0% of Nuvo Pharmaceuticals shares are owned by company insiders. Comparatively, 8.1% of Biofrontera shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings for Nuvo Pharmaceuticals and Biofrontera, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvo Pharmaceuticals	0	0	0	0	0.00
Biofrontera	1	1	1	0	2.00

Summary

Biofrontera beats Nuvo Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

About Nuvo Pharmaceuticals

Nuvo Pharmaceuticals, Inc. is a pharmaceutical company, which is engaged in developing innovative therapeutic pharmaceutical products. It operates through the following segments: Commercial Business, Production and Service Business, and Licensing and Royalty Business. The Commercial Business segment includes Blexten, Cambia, the canadian business for Resultz and Suvexx, and mature assets. The Production and Service Business segment supplies Pennsaid to Horizon for the U.S. market and is engaged in ongoing partnering efforts for Pennsaid. The Licensing and Royalty Business segment engages in the selling of Vimovo. The company was founded on August 22, 1983 and is headquartered in Mississauga, Canada.

About Biofrontera

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.